End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
27,050 KRW | +1.88% | +5.87% | +5.05% |
May. 22 | Hanwha Group Names New Head of North American Investments | MT |
May. 16 | White House moves to protect US solar manufacturers from Chinese competition | RE |
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Its low valuation, with P/E ratio at 8.72 and 3.5 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 37.96 for the 2024 fiscal year.
- The company appears to be poorly valued given its net asset value.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Life & Health Insurance
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+5.05% | 1.45B | B | ||
+13.39% | 78.89B | B- | ||
+9.44% | 51.46B | B+ | ||
+8.93% | 51.07B | B | ||
+20.90% | 46.59B | B+ | ||
+16.04% | 43.21B | B+ | ||
+23.95% | 39.69B | B | ||
-0.60% | 29.1B | B | ||
-6.79% | 27.94B | B- | ||
-14.27% | 26.05B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- A000880 Stock
- Ratings Hanwha Corporation